Capecitabine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Capecitabine market studied was anticipated to grow with a CAGR of 5.5% during the forecast period owing to the rising demand for target drug therapy to decrease the possible side effects without affecting normal cells. Increased demand for the capecitabine can be attributed to their antimetabolite activity that specifically works by interfering with DNA synthesis minimizing the severe adverse effects. Also, the growing global burden of patients diagnosed with cancer and tumors is likely to drive the market. As per the World Health Organization report, cancer is a leading cause of death worldwide and estimated that nearly 9.6 million deaths in 2018. Also, it is estimated that 627,000 women died from breast cancer accounting for about 15% of all cancer deaths among women across the globe. Also, a steep rise in healthcare expenditure, ongoing R&D activities in cancer treatment are likely to provide new opportunities for the market. Furthermore, growing awareness programs by governments and private organizations such as Cancer Care, Cancer Research UK, and Cancer Suraksha Scheme are anticipated to propel the global capecitabine market growth over the course of the period.

Key Market Trends

Breast Cancer by Indication is Expected to Hold the Largest Market Share in the Global Capecitabine Market

Breast cancer sub-segment is expected to account for the largest share in the market. Dominance can be attributed to the increased prescriptions of the drug as the gold standard due to their proven efficiency in the treatment of breast cancer. Furthermore, their advantages such as increased access, and availability in the form of oral dosage has enhanced convenience to patients. Also, increased prescriptions of capecitabine in combinational therapy along with docetaxel, pertuzumab, and trastuzumab to prolong overall survival in metastatic breast cancer further fuel the growth of the segment during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall capecitabine market throughout the forecast period. The dominance is due to the rising prevalence of the various types of cancer like colorectal cancer, colon cancer in the region. Growing incidences of cancer can be due to several factors like physical inactivity, obesity, stress, and a sedentary lifestyle. Also, a steep rise in the elderly population due to the presence of baby boomers during the forecast period in the United States results in higher revenue of the region.

For instance, as per the International Diabetes Federation in 2019, about 48 million adults in North America are living with diabetes, among which more than half of the patients are over the age of 65 and are expected to continue in the future. According to the American Cancer Society report, in 2017 about 135,430 new cases and 50,260 deaths were estimated due to colon and rectum cancer in the U.S.

Thus, a huge target population and increased disposable income in the United States fuels the market. Furthermore, the presence of key players such as Roche, Teva, and others conducting cancer clinical trials are expected to contribute to the significant revenue share in the global capecitabine market.

Competitive Landscape

The global capecitabine market is moderately competitive and consists of several major players. Few of the prominent players currently dominating the market are applying various strategies like acquiring the products or other companies to consolidate their market positions across the globe and while others are launching generic products. For example, in April 2019, Armas Pharmaceuticals, Inc launched a generic version of Roches’s Xeloda, a capecitabine product. Such product launches are expected to propel the market growth. Some of the companies which are currently dominating the market are Cipla Inc., Teva Pharmaceuticals USA Inc, F. Hoffmann-La Roche AG (Genentech, Inc.), Mylan N.V., and Hikma Pharmaceuticals PLC.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support